Therapeutic Advances in HER2-Mutated NSCLC

Dr. Edgardo Santos and Dr. Gilberto Lopes introduce the program and establish the clinical relevance of HER2-mutated NSCLC as an emerging target in thoracic oncology.

In this section, the discussion shifts to therapeutic advances in HER2-mutated NSCLC, with a particular focus on antibody-drug conjugates (ADCs) as a transformative treatment modality.

This segment addresses the safety profile and toxicity management of HER2-targeted ADCs, a critical consideration for oncologists integrating these therapies into routine practice.

In this segment, Drs. Santos and Lopes explore treatment sequencing strategies for patients with HER2-mutated NSCLC, a rapidly evolving area of clinical decision-making. The discussion addresses the current positioning of HER2-targeted therapies relative to chemotherapy and immunotherapy, particularly in the first-line setting.

Dr. Santos and Dr. Lopes address the incidence of brain metastases and management of central nervous system (CNS) metastases in patients with HER2-mutated NSCLC, a clinically significant challenge in thoracic oncology.

The discussion turns to mechanisms of resistance to HER2-targeted therapies and the implications for future research and clinical practice. Drs. Santos and Lopes note that, as with other targeted therapies, resistance inevitably develops, necessitating ongoing innovation.

This section provides practical insights that help oncologists bridge the gap between evidence and practice, enhancing the applicability of HER2-targeted therapies in diverse patient populations.

Drs. Santos and Lopes provide a forward-looking perspective on the future of HER2-targeted therapy in NSCLC, emphasizing ongoing clinical trials and anticipated paradigm shifts. They discuss the potential for earlier-line use of ADCs, as well as combination strategies that may further improve outcomes.